India is proposing an ambitious plan to substantially raise spending on providing free drugs for India’s 1.2 billion population. But there are doubts over the plan’s implementation. India wants to spend up to 300 billion rupees ($5.4 billion), or 0.5% of gross domestic product, on procuring drugs to be distributed through governmentrun hospitals and clinics by 2017. Currently, India spends about 60 billion rupees ($1.1 billion), or 0.1% of GDP.
Most government hospitals in India are overcrowded, understaffed and lack medicines and supplies. “Significant shortages in the number of doctors, nurses, paramedics and hospital beds per 1,000 population in India pose a great challenge for speedier
implementation of universal healthcare in the country,” said Tapan Ray, director general of the Organisation of Pharmaceutical Producers of India, or OPPI, a lobby group for Pharma MNCs in India.
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha Anup Soans
Read this to understand the reasons for the Govt's crackdown on Indian Pharma - Parliament committee report on CDSCO. Parliament was seized of unethical and unprofessional practices in 2012 itself.
Industry Monitor - Indian Healthcare Sector October 2014 (2)Debasish M Banerjee
This document provides an industry report on the Indian healthcare sector from October 2014. It includes sections on pharmaceuticals, industry statistics, product scans of x-ray machines and generic drugs, company and industry news, mergers and acquisitions, a company profile of Dr. Reddy's Laboratories, and upcoming events. Key highlights are the expected growth of the Indian pharmaceutical market to $55 billion by 2020, dominance of generic drugs, prevalence of counterfeit drugs, and focus on chronic disease segments and biologics.
This document is a dissertation report submitted by Nikhil Jhamb to Kurukshetra University in partial fulfillment of an MBA degree. The report analyzes the management information system reports of 10 pharmaceutical companies in Paonta Sahib, India. It includes an introduction on the pharmaceutical industry in India, profiles of the 10 companies studied, a chapter on management information systems, the research methodology used, an analysis and interpretation of data from the companies' MIS reports, findings from the study, and recommendations and conclusions. The key points provided on the pharmaceutical industry in India note that supply is higher for traditional therapeutic segments typical of a developing market, while demand is very high for certain therapeutic segments and will change as life expectancy and literacy
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
The document provides an overview of the pharmaceutical industry in India and analyzes two pharmaceutical companies - Eris Lifesciences and Granules. It discusses that the Indian pharmaceutical industry has low production costs and supplies over 50% of global generic drug demand. A SWOT analysis identifies strengths like low costs and chemistry skills, and weaknesses like price regulation. Eris Lifesciences and Granules were selected for analysis as they focus on producing drugs domestically rather than importing raw materials. Eris Lifesciences in particular has leading market shares, high margins, and growing profits.
The document provides an overview of the pharmaceutical industry in India and analyzes two pharmaceutical companies - Eris Lifesciences and Granules. It discusses that the Indian pharmaceutical industry has low production costs and supplies over 50% of global generic drug demand. A SWOT analysis identifies strengths like low costs and chemistry skills, and weaknesses like price regulation. Eris Lifesciences and Granules were selected for analysis as they focus on producing drugs domestically rather than importing raw materials. Eris Lifesciences in particular has leading market shares, high margins, and growing profits.
India is proposing an ambitious plan to substantially raise spending on providing free drugs for India’s 1.2 billion population. But there are doubts over the plan’s implementation. India wants to spend up to 300 billion rupees ($5.4 billion), or 0.5% of gross domestic product, on procuring drugs to be distributed through governmentrun hospitals and clinics by 2017. Currently, India spends about 60 billion rupees ($1.1 billion), or 0.1% of GDP.
Most government hospitals in India are overcrowded, understaffed and lack medicines and supplies. “Significant shortages in the number of doctors, nurses, paramedics and hospital beds per 1,000 population in India pose a great challenge for speedier
implementation of universal healthcare in the country,” said Tapan Ray, director general of the Organisation of Pharmaceutical Producers of India, or OPPI, a lobby group for Pharma MNCs in India.
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha Anup Soans
Read this to understand the reasons for the Govt's crackdown on Indian Pharma - Parliament committee report on CDSCO. Parliament was seized of unethical and unprofessional practices in 2012 itself.
Industry Monitor - Indian Healthcare Sector October 2014 (2)Debasish M Banerjee
This document provides an industry report on the Indian healthcare sector from October 2014. It includes sections on pharmaceuticals, industry statistics, product scans of x-ray machines and generic drugs, company and industry news, mergers and acquisitions, a company profile of Dr. Reddy's Laboratories, and upcoming events. Key highlights are the expected growth of the Indian pharmaceutical market to $55 billion by 2020, dominance of generic drugs, prevalence of counterfeit drugs, and focus on chronic disease segments and biologics.
This document is a dissertation report submitted by Nikhil Jhamb to Kurukshetra University in partial fulfillment of an MBA degree. The report analyzes the management information system reports of 10 pharmaceutical companies in Paonta Sahib, India. It includes an introduction on the pharmaceutical industry in India, profiles of the 10 companies studied, a chapter on management information systems, the research methodology used, an analysis and interpretation of data from the companies' MIS reports, findings from the study, and recommendations and conclusions. The key points provided on the pharmaceutical industry in India note that supply is higher for traditional therapeutic segments typical of a developing market, while demand is very high for certain therapeutic segments and will change as life expectancy and literacy
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
The document provides an overview of the pharmaceutical industry in India and analyzes two pharmaceutical companies - Eris Lifesciences and Granules. It discusses that the Indian pharmaceutical industry has low production costs and supplies over 50% of global generic drug demand. A SWOT analysis identifies strengths like low costs and chemistry skills, and weaknesses like price regulation. Eris Lifesciences and Granules were selected for analysis as they focus on producing drugs domestically rather than importing raw materials. Eris Lifesciences in particular has leading market shares, high margins, and growing profits.
The document provides an overview of the pharmaceutical industry in India and analyzes two pharmaceutical companies - Eris Lifesciences and Granules. It discusses that the Indian pharmaceutical industry has low production costs and supplies over 50% of global generic drug demand. A SWOT analysis identifies strengths like low costs and chemistry skills, and weaknesses like price regulation. Eris Lifesciences and Granules were selected for analysis as they focus on producing drugs domestically rather than importing raw materials. Eris Lifesciences in particular has leading market shares, high margins, and growing profits.
Brief Report on the Indian Pharmaceutical Industry - 2011david_singer
The document summarizes the pharmaceutical industry in India. It provides an overview of the industry, noting that it is highly fragmented with over 20,000 registered units and is a $4.5 billion industry growing annually by 8-9%. It also profiles some of the largest pharmaceutical companies in India, including Ranbaxy, Dr. Reddy's Laboratories, and Cipla, and discusses their operations, market shares, and R&D investments. The industry is a major exporter of generic drugs and has a competitive advantage due to its skilled workforce and cost-effective production capabilities.
This document discusses growth opportunities for the Indian pharmaceutical industry through 2025. It identifies 6 value creation factors that can accelerate growth: 1) new products and business models through innovation, 2) new therapies for existing treatments, 3) affordability, 4) access to healthcare, 5) pricing strategies, and 6) marketing efficiencies. The current Indian pharmaceutical market is estimated at $7.5 billion based on retail sales, hospital sales, and generic sales. The industry can target growth by expanding in rural and urban markets, increasing treatment rates for conditions like diabetes, and introducing new products and therapies.
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
The global sales of medicines reached $942 billion in 2011, a 5.1% increase from the previous year. This total is expected to reach $1.5 trillion by 2020 due to population growth and an aging population. However, the pharmaceutical industry faces issues such as losing $148 billion annually from 2012-2018 due to drugs going off patent and rising research and development costs of $800 million to $4 billion to bring a new drug to market. The Indian pharmaceutical industry has grown substantially over the past few decades but faces threats from increasing regulation and low-cost competition from other countries.
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Drug market structure (Pharma in Indian Scenario)hemant vyas
This document provides an overview of the pharmaceutical industry in India. It discusses the growth and structure of the industry, both globally and within India. It notes that while India is a major producer of generic drugs, its research and development spending and capabilities remain relatively low. The industry in India is characterized by high profitability and concentration among the largest companies.
India bariatric surgical devices market size, share & forecast 2025TechSci Research
According to www.techsciresearch.com latest Report- India bariatric surgical devices market is expected to grow at a formidable rate during the forecast period. The India bariatric surgical devices market is driven by the growing diabetic population especially Type 2 diabetes. Additionally.
Report URL- https://www.techsciresearch.com/report/india-bariatric-surgical-devices-market/4557.html
Competitive landscape of the pharma industry in india123sripal
The pharmaceutical industry in India began in 1930 with the establishment of Bengal Chemicals and Pharmaceutical Works. India's pharmaceutical market has grown significantly and is expected to reach $24-34 billion by 2016. The industry is divided into several segments including finished formulations, pharmaceutical drugs, biotechnology, and equipment. Major players in the industry include Lupin, Dr. Reddy's, Cipla, and Sun Pharma. The industry supplies over 70% of India's drug demands and exports products worldwide.
This document provides a directory of pharmaceutical manufacturing units in India for the year 2007. It lists pharmaceutical manufacturers from across India, divided by state. For Andhra Pradesh, it lists 60 formulation manufacturing units, providing information such as company name, address, telephone number, and email/website when available. The units are listed alphabetically by company name within the Andhra Pradesh section. It also notes that the directory contains information for 10563 total pharmaceutical manufacturers in India divided into formulation and bulk drug manufacturers.
Ervas Pharmaceuticals' mission is to make herbal wellness accessible to everyone and promote the belief that good health should be available to all. The company produces herbal medicines with the goal of improving health and wellness. Ervas focuses on natural and herbal remedies to help more people access affordable healthcare options.
Overview of the pharmaceutical industry of bangladeshSadman Prodhan
The document provides an overview of the pharmaceutical industry in Bangladesh. It notes that the industry was established in 1950 and now includes 231 companies with a market size of 76.5 billion BDT. The top 5 companies by market share are Square, Incepta, Beximco, Opsonin, and Eskayef. The industry supplies 97% of the domestic market and exports to 72 countries. A PESTEL analysis identifies various political, economic, social, technological, environmental and legal factors impacting the industry. A Porter's 5 forces analysis finds high rivalry among existing firms and a very high threat of new entrants. The document also compares Square Pharmaceuticals and Orion Pharma in terms of market position,
Bangladesh Pharmaceuticals Market & It's Future (for non pharma background)
if you need the slide please call +8801717678894 or email: shadhin1008@live.com
This document summarizes statistics on the clinical research industry. It finds that India has experienced strong growth in clinical trials in recent years and is emerging as a top destination for outsourced clinical research. While the Indian clinical research market is growing rapidly, it remains relatively small compared to the global market and there is a need for more trained professionals to support further industry expansion.
Market Research Report : Clinical trials market in india 2014 - SampleNetscribes, Inc.
The clinical trials market in India was valued at INR x1 billion in 2013 and is estimated to reach INR x2 billion by 2018, growing at a CAGR of y1%. India's share of the global clinical trials market was y2% in 2013. Key drivers of growth include lower costs, a large patient population, and increasing R&D spending by pharmaceutical companies. However, new regulations have also brought challenges such as delays in approval and a shortage of research professionals. The document provides an overview of the market size and growth drivers, government regulations, and major players in the clinical trials industry in India.
Challenges in indian pharmaceutical industry due to globalizationvishnugm
Globalisation is a process which involves economic inter-dependence of countries world-wide removing all barriers for economic integration as if the whole world is a single village. Obviously, in this process, the rich nations with their superior financial power, control the scenario and the poor and the developing nations are forced to integrate surrendering their economic independence knowing fully well what they are forced to accept is really prejudicial to their own interest.
Pakistan has a growing pharmaceutical market valued at $2.6 billion in 2015. Systemic anti-infectives and alimentary tract and metabolism drugs make up nearly half of total market share. The top 20 pharmaceutical companies, including GlaxoSmithKline and Abbott Laboratories, account for over 50% of total market value. Major trading partners for pharmaceutical imports and exports include Afghanistan, Denmark, Switzerland, and Germany.
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most”
“Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.
l Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards
India’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation.Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most”
“Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.
Brief Report on the Indian Pharmaceutical Industry - 2011david_singer
The document summarizes the pharmaceutical industry in India. It provides an overview of the industry, noting that it is highly fragmented with over 20,000 registered units and is a $4.5 billion industry growing annually by 8-9%. It also profiles some of the largest pharmaceutical companies in India, including Ranbaxy, Dr. Reddy's Laboratories, and Cipla, and discusses their operations, market shares, and R&D investments. The industry is a major exporter of generic drugs and has a competitive advantage due to its skilled workforce and cost-effective production capabilities.
This document discusses growth opportunities for the Indian pharmaceutical industry through 2025. It identifies 6 value creation factors that can accelerate growth: 1) new products and business models through innovation, 2) new therapies for existing treatments, 3) affordability, 4) access to healthcare, 5) pricing strategies, and 6) marketing efficiencies. The current Indian pharmaceutical market is estimated at $7.5 billion based on retail sales, hospital sales, and generic sales. The industry can target growth by expanding in rural and urban markets, increasing treatment rates for conditions like diabetes, and introducing new products and therapies.
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
The global sales of medicines reached $942 billion in 2011, a 5.1% increase from the previous year. This total is expected to reach $1.5 trillion by 2020 due to population growth and an aging population. However, the pharmaceutical industry faces issues such as losing $148 billion annually from 2012-2018 due to drugs going off patent and rising research and development costs of $800 million to $4 billion to bring a new drug to market. The Indian pharmaceutical industry has grown substantially over the past few decades but faces threats from increasing regulation and low-cost competition from other countries.
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Drug market structure (Pharma in Indian Scenario)hemant vyas
This document provides an overview of the pharmaceutical industry in India. It discusses the growth and structure of the industry, both globally and within India. It notes that while India is a major producer of generic drugs, its research and development spending and capabilities remain relatively low. The industry in India is characterized by high profitability and concentration among the largest companies.
India bariatric surgical devices market size, share & forecast 2025TechSci Research
According to www.techsciresearch.com latest Report- India bariatric surgical devices market is expected to grow at a formidable rate during the forecast period. The India bariatric surgical devices market is driven by the growing diabetic population especially Type 2 diabetes. Additionally.
Report URL- https://www.techsciresearch.com/report/india-bariatric-surgical-devices-market/4557.html
Competitive landscape of the pharma industry in india123sripal
The pharmaceutical industry in India began in 1930 with the establishment of Bengal Chemicals and Pharmaceutical Works. India's pharmaceutical market has grown significantly and is expected to reach $24-34 billion by 2016. The industry is divided into several segments including finished formulations, pharmaceutical drugs, biotechnology, and equipment. Major players in the industry include Lupin, Dr. Reddy's, Cipla, and Sun Pharma. The industry supplies over 70% of India's drug demands and exports products worldwide.
This document provides a directory of pharmaceutical manufacturing units in India for the year 2007. It lists pharmaceutical manufacturers from across India, divided by state. For Andhra Pradesh, it lists 60 formulation manufacturing units, providing information such as company name, address, telephone number, and email/website when available. The units are listed alphabetically by company name within the Andhra Pradesh section. It also notes that the directory contains information for 10563 total pharmaceutical manufacturers in India divided into formulation and bulk drug manufacturers.
Ervas Pharmaceuticals' mission is to make herbal wellness accessible to everyone and promote the belief that good health should be available to all. The company produces herbal medicines with the goal of improving health and wellness. Ervas focuses on natural and herbal remedies to help more people access affordable healthcare options.
Overview of the pharmaceutical industry of bangladeshSadman Prodhan
The document provides an overview of the pharmaceutical industry in Bangladesh. It notes that the industry was established in 1950 and now includes 231 companies with a market size of 76.5 billion BDT. The top 5 companies by market share are Square, Incepta, Beximco, Opsonin, and Eskayef. The industry supplies 97% of the domestic market and exports to 72 countries. A PESTEL analysis identifies various political, economic, social, technological, environmental and legal factors impacting the industry. A Porter's 5 forces analysis finds high rivalry among existing firms and a very high threat of new entrants. The document also compares Square Pharmaceuticals and Orion Pharma in terms of market position,
Bangladesh Pharmaceuticals Market & It's Future (for non pharma background)
if you need the slide please call +8801717678894 or email: shadhin1008@live.com
This document summarizes statistics on the clinical research industry. It finds that India has experienced strong growth in clinical trials in recent years and is emerging as a top destination for outsourced clinical research. While the Indian clinical research market is growing rapidly, it remains relatively small compared to the global market and there is a need for more trained professionals to support further industry expansion.
Market Research Report : Clinical trials market in india 2014 - SampleNetscribes, Inc.
The clinical trials market in India was valued at INR x1 billion in 2013 and is estimated to reach INR x2 billion by 2018, growing at a CAGR of y1%. India's share of the global clinical trials market was y2% in 2013. Key drivers of growth include lower costs, a large patient population, and increasing R&D spending by pharmaceutical companies. However, new regulations have also brought challenges such as delays in approval and a shortage of research professionals. The document provides an overview of the market size and growth drivers, government regulations, and major players in the clinical trials industry in India.
Challenges in indian pharmaceutical industry due to globalizationvishnugm
Globalisation is a process which involves economic inter-dependence of countries world-wide removing all barriers for economic integration as if the whole world is a single village. Obviously, in this process, the rich nations with their superior financial power, control the scenario and the poor and the developing nations are forced to integrate surrendering their economic independence knowing fully well what they are forced to accept is really prejudicial to their own interest.
Pakistan has a growing pharmaceutical market valued at $2.6 billion in 2015. Systemic anti-infectives and alimentary tract and metabolism drugs make up nearly half of total market share. The top 20 pharmaceutical companies, including GlaxoSmithKline and Abbott Laboratories, account for over 50% of total market value. Major trading partners for pharmaceutical imports and exports include Afghanistan, Denmark, Switzerland, and Germany.
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most”
“Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.
l Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards
India’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation.Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most”
“Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.
Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most”
“Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.
This document is a dissertation report submitted by Nikhil Jhamb to Kurukshetra University in partial fulfillment of an MBA degree. The report analyzes the management information system reports of 10 pharmaceutical companies in Paonta Sahib, India. It includes an introduction to the Indian pharmaceutical industry, profiles of the 10 companies studied, a description of the research methodology used, an analysis and interpretation of data from the companies' MIS reports, findings from the study, and recommendations and conclusions. The Indian pharmaceutical industry is a $4.5 billion industry that is highly fragmented across more than 20,000 registered units and is an important industry in India.
The document discusses opportunities and challenges facing India's pharmaceutical industry. It notes that as drug patents expire, Indian generic drug producers are well-positioned to expand globally. It also discusses how India is becoming an attractive location for multinational drug companies to outsource research, development, and manufacturing activities due to its scientific expertise and lower costs. Further, India's large population represents a major potential domestic market, though expanding access to medicines is challenging. The industry now has opportunities for both foreign and domestic firms to partner and leverage each other's strengths for mutual benefit.
This document is a project report submitted by Mr. Santosh Panchakshari Salgare to the Department of Management Sciences at Savitribai Phule Pune University. The project involved conducting a study to understand the prescription pattern of generic drugs at Hindustan Antibiotics Limited in Pimpri, Pune. The report includes an introduction to the pharmaceutical industry, company profile of Hindustan Antibiotics Limited, objectives, methodology, findings and analysis of the study, and conclusions and recommendations.
The document discusses the Indian pharmaceutical industry. It provides an overview of major players, the Indian and global scenarios, future outlook, and areas for boosting competitiveness. The industry has grown significantly over time and India is now a top producer and exporter of generic drugs globally. The outlook remains positive with the market expected to reach $74 billion by 2020 and become one of the top ten markets worldwide. However, further investment in R&D and addressing regulatory issues can help strengthen the industry.
Working Capital Management on Cadila Healthcare Limited.Moin Panja
This document provides background information on the history and development of the Indian pharmaceutical industry. It discusses how the industry grew after the 1970 Patent Act which removed composition patents from drugs and shortened process patents. This allowed Indian companies to enter the market and become a major global supplier of generic drugs. It also outlines key statistics on the current size and growth of the Indian pharmaceutical industry, which is now the 3rd largest producer globally and poised to become a $20 billion industry by 2015. The document notes that while many players are small-medium enterprises, foreign companies still control a large portion of the domestic market in India.
This document provides a history of the Indian pharmaceutical industry. It discusses how the industry grew after economic liberalization in the 1990s allowed Indian companies to enter generic drug manufacturing. It overtook the market share of multinational companies. The industry is now the 3rd largest producer globally by volume. It discusses the key players, regulations around patents, growth of exports, and challenges around research and development. It also provides an overview of the biotech sector in India and how it is growing but still smaller than the pharmaceutical industry.
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssueAnup Soans
1. Draft Pharma Policy: The Good, The Bad and The Ugly...............................................1
Interview with Sunil Attavar
2. Career Brand Plan: A Career Stepping
Stone..........................................................9
Soham Wagh
3. Succeeding as Country GM at GSK: A Whitepaper..............................................12
Sundar Ramachandran
4. Role of Digital in the Customer Journey ....................................................................21
Salil Kallianpur
5. Executive Function Disorder .................24
Vivek Hattangadi
The global pharmaceutical manufacturing market is expected to grow significantly from 2017 to 2022 due to advantages of continuous manufacturing processes. The Indian pharmaceutical market is the third largest by volume and is a major exporter of generic drugs. The market is expected to grow to $55 billion by 2020 due to investments in production and R&D from companies and initiatives by the Indian government to promote pharmaceutical industry growth.
This document provides comments on India's proposed policy regarding compulsory licensing of pharmaceutical patents. It agrees with the goals of maintaining access to medicines and India's health security. However, it raises several concerns regarding terms of voluntary licensing that could constitute abuse of monopoly. It also argues that the policy needs convergence with other policies around essential medicines, importation, competition, and intellectual property to truly benefit patients. The document advocates for India to take a leadership role in enabling access to affordable medicines globally.
My recommendations at FICCI as Vice Chair of personalised healthcare and genomics committee
Kapil Khandelwal
QuoteUnquote with KK
www.kapilkhandelwal.com
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Global pharmaceutical companies are looking to India for growth opportunities due to pricing pressures and slower growth in traditional Western markets. India represents a large potential market due to its growing and increasingly affluent population, as well as changing disease burdens like a rise in chronic diseases. It also offers lower costs for activities like clinical trials and manufacturing capabilities in generics and vaccines. Global pharma companies have various options for partnering with Indian companies including contract manufacturing, licensing, joint ventures, and wholly owned subsidiaries. However, India also faces challenges like infrastructure issues, intellectual property protection, and a price sensitive domestic market.
Survey report pharmaceutical marketing ethical and responsible conductbrandsynapse
The survey found that over 50% of respondents believe that guidelines from the Medical Council of India and Department of Pharmaceuticals on interactions between pharmaceutical companies and healthcare professionals will not be effective in ensuring ethical marketing of drugs in India due to a lack of legislative support and potential for manipulation. Additionally, around 72% felt that the Medical Council was not strongly enforcing its own ethics guidelines. Only 36% believed the Medical Council's guidelines would impact drug sales.
1) By 2020, the Indian pharmaceutical industry is projected to grow to $50 billion and become one of the top 10 pharmaceutical markets globally, driven by strong domestic demand and increased exports.
2) Generics are expected to continue dominating the market, accounting for around 90% of the pharmaceutical formulation market. Patent-protected drugs will make up about 10% of the market.
3) Increased healthcare infrastructure investment, rising incomes, health insurance expansion, and government programs are expected to drive growth in domestic pharmaceutical demand and help increase accessibility of drugs across India. Chronic diseases will account for over half of the pharmaceutical market.
The document provides an overview of the Ayurvedic medicine industry in India. It discusses that the industry is made up of thousands of small companies and neighborhood pharmacies as well as less than a dozen major companies that dominate the market. It notes that Ayurvedic medicines are considered fast moving consumer goods. The document also provides background on Ayurvedic medicine practices and principles. It analyzes the market size and growth of the pharmaceutical industry in India, including its exports and position as a global leader in generic drugs. SWOT analysis identifies strengths such as agricultural and expertise resources, and weaknesses like lack of awareness and support.
Similar to Pharma Summit - Gujarat Vibrant 2013 (20)
- India's urban population is growing rapidly and is projected to increase significantly by 2030, with many large cities.
- The Indian government has implemented various initiatives like Smart Cities Mission, AMRUT, and Housing for All to improve urban infrastructure and quality of life.
- Gujarat has a high level of urbanization compared to India overall and its cities are growing. The state government has undertaken initiatives like Smart Cities, affordable housing programs, and cleanliness drives to develop sustainable urban areas.
- Key projects in Gujarat include the Smart Cities of Ahmedabad, Surat, etc., the GIFT City financial hub, and the proposed Dholera SIR greenfield city.
Tourism industry the Gujarat Experience SectorVibrant Gujarat
This presentation details the overview of the tourism sector of India & Gujarat. It highlights the business opportunities present in the sector owing to robust growth in tourist inflow in the state. Various government incentives & policies are also listed to promote investment & cinematic tourism
This presentation highlights the strength of the textile sector in India as well as Gujarat. Detailing the strong manufacturing capacity as well as the easy availability of raw materials, the presentation makes a strong case for the immense business & investment opportunities present in the sector.
Highlighting the government’s focus on Skill Development to achieve economic & social development through the country’s huge active population (between 15-45 years), the presentation details the changing scenario of the skill development sector in India and the state of Gujarat.
The mammoth energy requirements of India coupled with the strong push being provided by the government to renewable sources of energy makes this sector a lucrative business prospect. This presentation details the overview of the renewable energy sector in India as well as Gujarat and highlights the business opportunities available within the sector.
This presentation details the overall scenario of the pharmaceutical sector in India as well as the state of Gujarat. The presentation highlights the investment & business opportunities present in the sector owing to the robust growth of the sector in India as well as Gujarat. Various government assistance schemes & incentives further augment the business potential of the sector.
This presentation gives an overview of the Micro, Small & Medium Enterprise sector in the state of Gujarat as well as India. While detailing the various incentives & schemes given by the government to different MSMEs, the presentation makes a strong case for growth of MSMEs in the state through the assistance provided by the government under Industrial policy 2015
Mega projects avenues for-investment in Gujarat SectorVibrant Gujarat
Gujarat has undertaken many mega infrastructure projects to develop sectors like ports, roads, railways, airports, power, water and urban transportation. It offers opportunities for investment in special investment regions like Dholera which covers 920 sqkm, and sectors like petrochemicals at the Petroleum, Chemicals and Petrochemicals Investment Region. The state also promotes the Gujarat International Finance Tec (GIFT) City, special economic zones, industrial parks and projects like the Statue of Unity. Gujarat has a robust infrastructure and policy initiatives that facilitate private investments in infrastructure development.
Information Technology and Information Technology Enabled Services SectorVibrant Gujarat
Highlighting the value proposition of the ever growing IT-ITes Sector in India, this presentation gives an overall idea about the future of the sector in India as well as Gujarat. It mentions the various initiatives, incentives and schemes launched by the Government of India and the Government of Gujarat to promote business and investment in the sector.
Detailing the overall profile of the Healthcare sector in India and Gujarat, this presentation makes a point for the immense business & investment opportunities present in the sector owing to government initiatives & schemes to achieve accessible, affordable & quality healthcare for all.
This presentation details the overall scenario for the Gems & Jewellery Sector in India as well as Gujarat. It highlights the business & investment opportunities present in the sector and also the government initiatives and interventions.
This presentation details the overall profile of the environment sector. It highlights the overview of the sector and also lays down guidelines for environment conservation. Lastly, it presents the current business and growth opportunities in the sector for sustainable development.
Detailing the profile of the engineering sector, this presentation highlights the size and scale of the industry in the nation as well as the future path for development of the industry. It lays down key FDI polices as well as the current business opportunities.
Electronic Sytem Sesign and Manufacturing SectorVibrant Gujarat
This presentation profiles the Electronic System Design and Manufacturing (ESDM) sector presenting the key facts & figures, policy interventions, electronics policy of Gujarat state and current business and growth opportunities.
Presenting the overall profile of the Chemical and petrochemical sector, this presentation highlights the current scenario of the industry, policy intervention, advantages of the industry and current business opportunities
This presentation on the biotechnology sector details the initiatives, infrastructure and policies developed by the government to promote growth of the sector and also highlight the current business opportunities present in this sector.
This presentation imparts a complete overview of Gujarat’s Forest Sector including information about the government initiatives, projects and schemes for collaboration opportunities as well as sustainable development by preserving the biodiversity & forest ecosystem
This presentation highlights the overview and subsidiaries of the agro and food processing sector in India & Gujarat. It details the major initiatives taken up by the government in terms of policies as well as infrastructure to promote industries and investments in the sector.
This presentation details the overview of the aerospace & defense sector. It highlights the current scenario of the sector in India as well Gujarat and also features details about government policies and Make in India initiative to develop industries & promote investment in the sector.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
1. Report on
“11th edition of Pharma Summit 2013”
Date: 31st October, 2013 Venue: Hotel The Lalit, Mumbai
Organised by Knowledge Partner Supported By
2. 2
The 11th edition of Pharma Summit 2013: a flagship event conducted by CII was held in Mumbai on 31st October 2013. The event saw participations from about 30 executives across pharmaceutical Industry, policy makers, academia, scientists, investors, technologists, and entrepreneurs.
On the backdrop of changing regulatory landscape in India and introduction of new drug pricing policy, FDI restrictions, patent protection, and compulsory licensing; the Indian Pharma Summit 2013 focused on how the Pharma industry can navigate through the regulatory hurdles and chart its strategies for growth.
The occasion was graced by distinguished speakers such as Dr Shri Rajiv Modi, Dr Shri H G Koshia, Dr Shri Hasit Joshipura, Shri J P Parswani, Shri Sujay Shetty, Shri Ninad Karpe; by sharing their knowledge and guiding the audience through their addresses.
The event incorporated CEO’s Interactive roundtables on following themes to set a perspective on the Indian Pharmaceutical Industry:
India Pharma Inc.: Regulatory Impact on Indian Pharma India Pharma Inc.: Spotlight on Maharashtra and Health Insurance India Pharma Inc.: Clinical Trials in India – Regulatory Challenges and Suggestions on the Way Forward India Pharma Inc.: Improving Sales Force Effectiveness through the Influx of Technology
Shri Ninad Karpe (Chairman, CII Maharashtra State Council) inaugurated the summit and welcomed the audience. In his address he mentioned that Indian pharmaceutical market (IPM) is the third largest market by volume and fourth largest by value across the globe. The Growth of the Industry has been good in the recent past, but is concentrated in a particular zone.
Shri J P Parswani (Executive Director, Cadila Pharmaceuticals Ltd.) briefed about the summit and its objectives. In his address he mentioned that delays in clinical trial approvals, uncertainties over the FDI policy, a uniform code for sales and marketing practices and compulsory licensing have affected growth of the Indian pharmaceutical market (IPM). The slowdown was also evident from the number of new product launches, which has gone down from approximately 1900 in year 2010 to 1700 in year 2012. However he stated that the slowdown provides the sector with an opportunity. “Big data, cloud computing, and networking
2
11
5
5
4
3
Industry Associations
Pharmascetical Industry
Poicy Maker
Consultant
Entreprenuers
Academias
3. 3
are changing the way business is being done in India”, he said and urged the sectors to adapt to the changes.
A joint CII-PwC report titled, ‘India Pharma Inc: Changing Landscape of Indian Pharma Industry’ was released during the event. The report emphasized on the changing landscape of the Indian pharmaceutical industry, the regulatory hurdles and the emerging technologies to achieve a sustainable and compliant long- term growth.
According to the report, the Indian pharmaceutical market (IPM) which is currently valued at INR 72,069 crore, has experienced a slowdown where its growth has declined from 16.6% in 2012 to 9.8% in 2013. This was attributed to new drug pricing policy and the regulatory interventions over the last year. Additionally, the implementation of the National
Pharmaceutical Pricing Policy 2012 by the Government of India has reportedly eroded margins for retailers and stockists, respectively from 20% and 10% to 16% and 8%.
While suggesting a way out, Shri Sujay Shetty (Partner – India Pharma Life Sciences Leader, PwC India) added that, “The economic environment in India is tougher now than ever before. While pharma companies focus their attention on measures to combat the growth slowdown, they will need to work with the government and other stakeholders to discuss and resolve regulatory challenges. Resolving the impasse with clinical trials is critical both for patients and India's ambition to innovate.”
Dr Shri Rajiv Modi (Chairman - CII Pharma Summit 2013 & CII Gujarat State Council and chairman and Managing Director, Cadila Pharmaceuticals), seconded this fact and added, "India has had an efficient pharmaceutical industry, which has been making affordable drugs not just for the Indian markets but has also been exporting them to the world. The sector is currently experiencing slow growth. Henceforth, both the Indian and foreign companies operating in India will have to device suitable strategies in order to be in the top 10 global markets by 2020."
Highlighting India’s advantage as an attractive destination for clinical trials, Dr Shri H G Khosia (Commissioner, Food and Drug Administration, Government of Gujarat) mentioned, “India is a blessed market with a genetically varied people, which makes it good for clinical trials, but due to PIL (public interest litigations) in court, clinical trials have come down. Hence when a PIL is filed, the sector should counter it by giving the correct picture.”
4. 4
The CII-PwC report too emphasized the importance of clinical trials in India. It mentioned that, Clinical trials are an inherent part of the drug development process and cannot be dispensed with. The continuing search for new therapies and cost-effective alternatives to existing therapies will be realised in practice only after comprehensive clinical trials are conducted in India.
Conclusion
In a nutshell, the panel members acknowledged that the clinical research industry need to liaise closely with the government, towards development of regulatory mechanism that allows sound and ethically correct trials which would benefit patients at large across the country.
Other dignitaries who attended the panel discussions included – Shri K V Subramaniam (President & Chief Executive Officer Reliance Life Sciences); Dr Safia Rizvi (Managing Director, UCB India Private Ltd.); Shri Anuj Reddy (Vice President – Business Development, Wockhardt Ltd.); Shri Krishnakumar Sankaranarayanan (Associate Director - Pharma Life Sciences, PwC India).